Autres langues Orexo AB

Actions

ORX

SE0000736415

Produits pharmaceutiques

Temps réel estimé Cboe Europe 10:48:29 31/08/2026			Varia. 5j.	Varia. 1 janv.
14,23 ^SEK	+6,35%		+7,76%	-52,03%

09:34	La Bourse de Stockholm inchangée en début de séance lundi	FW
09:23	Orexo proche d'un accord avec le DOJ : DNB Carnegie anticipe une issue favorable - analyse sponsorisée	FW

Autres langues

09:15	Orexo: Reaches a non-binding settlement with DOJ
08:42	Orexo Reaches Preliminary $4 Million Settlement for US Department of Justice Probe
08:01	Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice
17/07	Orexo: Weak Q2, with potential H2 catalysts nearing – Q2 review
16/07	Orexo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
16/07	Orexo AB Opens the Process to Look at Financing Opportunities
16/07	Orexo : Audiocast (engelska)
16/07	Orexo Q2 2026 Interim Report
09/06	Orexo AB Announces Appointment of Raheleh Nassaji as Senior Vice President Business Development
09/06	Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships
19/05	Orexo announces positive outcome from an in-vivo study of Ox390
19/05	Orexo AB Announces Positive Outcome from In-Vivo Study of OX390
19/05	Orexo: Promising early-stage data
19/05	Orexo announces positive pre-clinical data for nasal atipamezole using Amorphox technology
19/05	Orexo announces positive outcome from an in-vivo study of OX390
07/05	Report from Orexo AB’s annual general meeting May 7 2026
29/04	Orexo: Better visibility, few near-term catalysts – Q1 review
28/04	Orexo : Earnings Call Q1 2026 (engelska)
28/04	Orexo : Earnings Call Q1 2026
28/04	Orexo : Q1 2026 Interim Report MASTER
28/04	Orexo AB reports Q1 2026 net revenue of SEK 5.0 million
28/04	Orexo reports Q1 loss of SEK 105.2 million
28/04	Orexo : Q1 2026 Interim Report 2026
28/04	Orexo : Audiocast
28/04	Orexo Q1 2026 Interim Report